New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Asklepios Kliniken · ISIN: DE000A0ETLQ3 · EQS - Company News (31 News)
Country: Germany · Primary market: Germany · EQS NID: 2136894
14 May 2025 10:00AM

Stable business performance in Q1 2025


EQS-News: Asklepios Kliniken / Key word(s): Quarterly / Interim Statement/Quarter Results
Asklepios Group: Stable business performance in Q1 2025

14.05.2025 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Asklepios Group: Stable business performance in Q1 2025

Hamburg, 14 May 2025. Asklepios Kliniken GmbH & Co. KGaA records stable business performance in Q1 2025.

From January to March 2025, the Asklepios Group’s healthcare facilities treated a total of 954,522 patients, 3.8% more than in the same period of the previous year (3M 2024: 919,532). Compared with the same period of the previous year, the number of inpatients treated increased to 196,129 (3M 2024: 196,297). In the area of outpatient care, an increase to 757,393 was recorded (3M 2024: 723,235).

Revenues of the Asklepios Group saw a 10.2% increase to reach EUR 1.56 billion in the first quarter of 2025 (2024: EUR 1.41 billion. Consolidated net income (EAT) for January to March 2025 totalled EUR 22.5 million (3M 2024: EUR 18.5 million). The EAT margin was 1.4% (3M 2024: 1.3%). Investments in the first quarter of 2025 totalled EUR 69.5 million (3M 2024: EUR 67.4 million).

As at 31 March 2025, the Asklepios Group enjoys a stable financial position. The equity capital ratio was 30.4% as at 31 March 2025 (31 December 2024: 30.5%). The net debt ratio stood at 2.8x (31 December 2024: 2.9x).

About Asklepios

Asklepios Kliniken is one of the leading operators of private hospitals and healthcare facilities in Germany. The hospital group has an established track record for delivering high-quality medical care to its patients with a clear commitment to medical quality, innovation and social responsibility. Currently, the Asklepios Group has some 160 healthcare facilities throughout Germany. These include acute hospitals of all care levels, university hospitals, specialised clinics, psychiatric and forensic facilities, rehabilitation hospitals, nursing homes and medical care centres. During financial year 2024, over 3.6 million patients were treated at Asklepios’ healthcare facilities. The Group employs more than 70,000 persons.

The Quarterly Statement as at 31 March 2025 can be accessed at Asklepios - Publikationen.

IR contact:
Mirjam Constantin
Head of Corporate & ESG Reporting/Investor Relations
Asklepios Kliniken GmbH & Co. KGaA
Debusweg 3 - 61462 Königstein-Falkenstein
Tel: +49 61 74 90-1166
ir@asklepios.com

PR contact:
Rune Hoffmann
Head of Corporate Communications & Marketing
Asklepios Kliniken GmbH & Co. KGaA
Rübenkamp 226 - 22307 Hamburg
Tel.: +49 40 1818-82 6630
Fax: +49 40 1818-82 6639 
presse@asklepios.com

Visit Asklepios on the Internet, Facebook or YouTube:
www.asklepios.com
gesundleben.asklepios.com
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken
Nursing blog: “Wir sind Pflege

Sign up for the Asklepios Newsletter:
https://www.asklepios.com/konzern/newsletter-anmeldung/



14.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


2136894  14.05.2025 CET/CEST

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.